Actively Recruiting
Eltrombopag for Peripheral Blood Stem Cell Harvest
Led by National Taiwan University Hospital · Updated on 2024-10-18
46
Participants Needed
1
Research Sites
132 weeks
Total Duration
On this page
Sponsors
N
National Taiwan University Hospital
Lead Sponsor
N
Novartis
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this clinical trial is to explore the activity of eltrombopag in lymphoma patients receiving autologous hematopoietic stem cell harvest. The main questions it aims to answer are: * Determine the efficacy of adding eltrombopag during autologous hematopoietic stem cell mobilization and harvest. * Determine the pharmacokinetics and pharmacodynamics of serum eltrombopag concentration, circulating CD34+ cells during autologous hematopoietic stem cell mobilization. Participants will receiving additional eltrombopag during stem cell harvest procedure. The amount of harvested stem cells will be compared with historical group to see if eltrombopag could increase the amount of harvested stem cells.
CONDITIONS
Official Title
Eltrombopag for Peripheral Blood Stem Cell Harvest
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Diagnosed with Hodgkin lymphoma or non-Hodgkin lymphoma
- Have complete response, partial response, or stable disease after at least 2 treatment cycles
- Planned to receive ESHAP chemotherapy with or without monoclonal antibody for stem cell mobilization
- Of East-Asian heritage
You will not qualify if you...
- History of vascular thromboembolic event
- Platelet count greater than 1000k/µL
- Documented cytogenetic abnormalities in marrow blood
- Currently receiving eltrombopag
- History of severe (grade III-IV) hepatotoxicity to eltrombopag 75 mg/day
- Life-threatening allergic reactions to eltrombopag
- Baseline liver enzymes (AST, ALT) or bilirubin more than 3 times upper normal limit
- Pregnancy or breastfeeding
- Hepatitis C patients receiving interferon and ribavirin treatment
- Active cancer other than lymphoma
- Eastern Cooperative Oncology Group (ECOG) performance status 3-4
- Moribund status with likely death within 30 days due to severe organ disease
- Unable to understand the study or give informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
National Taiwan University Hospital
Taipei, Taiwan
Actively Recruiting
Research Team
T
Ta-Chuan Yu, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here